ClinicalTrials.gg
Active, not recruitingNCT06610526Updated Oct 30, 2026

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

A Phase 4 interventional study of Dapagliflozin in Chronic Kidney Disease, sponsored by AstraZeneca. Active, not recruiting at 34 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
731
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
7th of 40
731 · median 100
Started
2024
with 5 others
Phase 4
11 of 40
5 open now
Primary completion
2027-05
later than 12 of 20 live
Registered
25th of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 7th largest by enrollment, is one of 6 that started in 2024, is one of 11 in phase 4, reaches primary completion later than 12 of the 20 other live ones, and was the 25th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.

Read the detailed description

This is an interventional, multicentre, Phase IV, single-arm, open-label study to investigate the efficacy and safety of dapagliflozin to prevent the progression of chronic kidney disease in Chinese adult patients.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study specific procedures
  • Chinese Female or male aged ≥ 18 years at the time of consent
  • ≥ 25 and ≤ 75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1
  • Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥ 200 and ≤ 5000 mg/g at visit 1
  • Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically

Exclusion criteria

Exclusion Criteria:

  • Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasmic antibodies-associated vasculitis
  • Receiving cytotoxic therapy, therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
  • History of organ transplantation
  • Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
  • T1DM
  • class IV Congestive Heart Failure at the time of enrolment
  • MI, unstable angina, stroke or within 12 weeks prior to enrolment
  • Coronary revascularization (PCI or CABG) or valvular repair/replacement within 12 weeks prior to enrolment
  • Any condition outside the renal and CV disease area, such as but not limited to , with a of less than 2 years based on investigator´s clinical judgement
  • Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma)
  • Hepatic impairment ( or ALT > 3 × ; or total > 2 × ULN at time of enrolment). An solated increase in bilirubin in patients with known Gilbert's syndrome is not a reason for exclusion
  • Known blood-borne diseases
  • Women of (ie, those who are not chemically or surgically sterilised or who are not ) who are not willing to use a medically accepted method of that is considered reliable in the judgment of the investigator, from the time of signing the throughout the study and 4 weeks thereafter, OR women who have a positive pregnancy test at enrolment OR women who are breast-feeding
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or site personnel)
  • Previous enrolled in the present study
  • Participation in another clinical study with a study intervention during the last month prior to enrolment
  • Inability of the patient, in the opinion of the investigator, to understand and/or comply with study intervention, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
731 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin 10 mg once daily

    Drug: Dapagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death.

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

Secondary outcomes

  1. Percentage change in UACR from baseline

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

  2. Time to the first occurrence of any of the components of the composite: ≥ 50% sustained decline in eGFR or Reaching ESRD or Renal death

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

  3. Time to the first occurrence of either of the components of the composite: CV death or Hospitalization for heart failure

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

  4. Time to death from any cause

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

  5. Measure the change in eGFR over time from baseline to the end of treatment and from first on treatment measurement to end of treatment

    Data is reported as descriptive statistics.

    Time frame: Up to a median follow-up time of 24 months

  6. To describe the safety profile in Chinese adult patients with CKD treated with dapagliflozin: SAE, DAEs, and clinical chemistry/haematology parameters

    * The number and percent of subjects with SAE and DAE, and the total number of SAE and DAEs will be provided. * The result and the change from baseline of each clinical chemistry/haematology tests will be summarized at each scheduled visit using summary statistics based on the FAS.

    Time frame: From the administration of study intervention throughout the study until and including the patient's last visit, up to a median follow-up time of 24 months

07

Study locations

34 sites
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100068, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 102206, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Dongguan, 523059, China
  • Research Site
    Foshan, 528308, China
  • Research Site
    Fuyang, 236012, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Ganzhou, 341099, China
  • Research Site
    Harbin, 150000, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Huaian, 223399, China
  • Research Site
    Huizhou, 516001, China
  • Research Site
    Jilin City, 132011, China
  • Research Site
    Jinan, 250014, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Linyi, 276199, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200090, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Taian, 271099, China
  • Research Site
    Tianjin, 300121, China
  • Research Site
    Wuhu, 241000, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Xi'an, 710000, China
  • Research Site
    Xiamen, 361004, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.

Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Sep 24, 2024
StartActual
Aug 23, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06610526
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Aug 23, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Oct 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion